RecruitingRecruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986 · Novartis
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
About this study
This study will consist of two phases:
1. The escalation phase (Ib) will consist of provisionally three dose level cohorts of 3-6 participants investigating the safety, tolerability, and to determine the recommended dose for expansion (RDE) of AMO959 with standard dose of AAA617 +/- ARPI (abiraterone or enzalutamide). Initially AMO959 monotherapy will be administered, and then AMO959 will be given along with AAA617 in the same participants. Dose escalation meetings (DEMs) will occur when all participants in a dose level cohort have completed the DLT evaluation period or have experienced a DLT prior to the end of the evaluation period.
2. The Phase II will follow with 25 participants per arm randomized in a 1:1:1 ratio treated at the RDE(s) of AMO959 along with AAA617 and ARPI (abiraterone or enzalutamide) and AAA617 and ARPI (abiraterone or enzalutamide).
Eligibility criteria
Key Inclusion Criteria:
* Signed informed consent must be obtained prior to participation in the study.
* Participants must be adults ≥ 18 years of age.
* Participants must have an ECOG performance status of 0 to 2.
* Participants must have histologically confirmed adenocarcinoma of the prostate. Participants with other histology (e.g. neuroendocrine, intraductal subtype) are not eligible.
* Phase Ib: Prior exposure of up to 1 line of taxane-based chemotherapy is permissible. Phase II: Participants must not have received taxane-based chemotherapy in mCRPC setting (allowed in mHSPC setting).
* Participants must have PSMA-PET positive disease assessed by using a PSMA imaging agent that is approved as per protocol and are eligible as determined by the sponsor's central reading rules.
* Castration level of testosterone (\< 50 ng/dL), and/or use of concomitant ADT
* Participant must have been diagnosed with mCRPC with documented progressive disease while on treatment with ARPI in mHSPC or earlier setting as their last treatment (and did not progress on more than one ARPI), based on at least 1 of the following criteria:
* Serum/plasma PSA progression is defined as 2 increases in PSA measured at least 1 week apart. The minimal start value is 2.0 ng/mL; 1.0 ng/mL is the minimal starting value if confirmed rise in PSA is the only indication of progression as per PCWG3 guidelines.
* Soft-tissue progression defined PCWG3-modified RECIST v1.1 (Eisenhauer et al 2009, Scher et al 2016).
* Progression of bone disease: 2 new lesions; only positivity on the bone scan defines metastatic disease to bone (PCWG3 criteria Scher et al 2016).
Key Exclusion Criteria:
* Concurrent local (radiation therapy to the prostate with curative intent or other prostate antineoplastic ablative procedures) or systemic (hormonal ablation, chemotherapy, immunotherapy, , RLTs) antineoplastic treatments, or within 28 days of enrollment (Phase Ib) or randomization (Phase II)
* Prior treatment with any RLT or PSMA-targeted agents (approved or investigational)
* Any other investigational agents within 28 days prior to first dose of any study treatment
* Concurrent serious medical conditions that may interfere with study procedures or followup
* Participants with a history of CNS metastases must have received therapy (surgery, whole brain radiation therapy, stereotactic radiosurgery) and be neurologically stable, asymptomatic, and not taking corticosteroids for the purpose of maintaining neurologic integrity.
Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 123 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-12-05
Estimated completion: 2029-09-13
Last updated: 2026-10-15
Interventions
Drug: AMO959Radiation: AAA617Drug: EnzalutamideDrug: Abiraterone
Primary outcomes
- • Phase Ib: Incidence rate of Dose-limiting toxicities (DLTs) (Up to 42 days after the first AAA617 dose administration)
- • Phase Ib: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs) (From date of start of study treatment, assessed up to approximately 45 months)
- • Phase Ib: Number of Participants with dose adjustments (From date of start of study treatment, assessed up to approximately 24 months)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · +41613241111
InvestigatorNovartis Pharmaceuticals · study_director, Novartis Pharmaceuticals
All locations (25)
VA Greater LA Healthcare SystemRecruiting
Los Angeles, California, United States
Duke Univ Medical CenterRecruiting
Durham, North Carolina, United States
Rio Grande UrologyRecruiting
El Paso, Texas, United States
Utah Intermountain Medical CenterRecruiting
Murray, Utah, United States
Novartis Investigative SiteRecruiting
Malvern, Victoria, Australia
Novartis Investigative SiteRecruiting
Melbourne, Victoria, Australia
Novartis Investigative SiteRecruiting
Melbourne, Victoria, Australia
Novartis Investigative SiteRecruiting
Murdoch, Western Australia, Australia
Novartis Investigative SiteRecruiting
Bordeaux, France
Novartis Investigative SiteRecruiting
Clermont-Ferrand, France
Novartis Investigative SiteRecruiting
Nantes, France
Novartis Investigative SiteRecruiting
Villejuif, France
Novartis Investigative SiteRecruiting
Dresden, Saxony, Germany
Novartis Investigative SiteRecruiting
Essen, Germany
Novartis Investigative SiteRecruiting
München, Germany
Novartis Investigative SiteRecruiting
Stuttgart, Germany
Novartis Investigative SiteRecruiting
Cona, FE, Italy
Novartis Investigative SiteRecruiting
Milan, MI, Italy
Novartis Investigative SiteRecruiting
Naples, Italy
Novartis Investigative SiteRecruiting
Sapporo, Hokkaido, Japan
Novartis Investigative SiteRecruiting
Fukuoka, Japan
Novartis Investigative SiteRecruiting
Granada, Andalusia, Spain
Novartis Investigative SiteRecruiting
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative SiteRecruiting
Barcelona, Spain
Novartis Investigative SiteRecruiting
Madrid, Spain